Article info

Download PDFPDF
Extended report
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

Authors

  1. Correspondence to Dr Denis Poddubnyy, Rheumatology, Med. Department I, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany; denis.poddubnyy{at}charite.de
View Full Text

Citation

Poddubnyy D, Hermann KA, Callhoff J, et al
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

Publication history

  • Received July 7, 2013
  • Revised November 22, 2013
  • Accepted December 10, 2013
  • First published January 3, 2014.
Online issue publication 
April 04, 2014

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.